Gynecology Trials

NRG-GY006

NRG-GY006 – a randomized phase II trial of radiation therapy and cisplatin alone or in combination with intravenous tripine in women with newly diagnosed bulky stage IB2, stage II, IIIB, or IVA cancer of the uterine cervix or stage II-IVA vaginal cancer.

What type of cancer? What stage?
1. Cervix or vaginal cancer.
Who is eligible?
1. Women who will be treated with radiation.
How will I be treated?
1. Patients will be randomized to receive Triapine, along with standard curative therapy. Tripine is a biologic drug, a ribonucleotide reductase inhibitor.

For physicians: more information about this specific trial at clinicaltrials.gov.

Related locations